RH5: rationally-designed malaria vaccine antigen improving efficacy
Trends in Parasitology · 2024
DOI: 10.1016/j.pt.2024.09.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Parasitology, 2024. Verfasst von Eizo Takashima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama 790-8577, Japan. Hauptthemen laut MEDLINE: Antigens, Protozoan, Malaria Vaccines, Malaria, Falciparum, Plasmodium falciparum. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a unique asexual blood-stage malaria vaccine candidate because of its high conservation and essential biological function of binding to basigin on the erythrocyte surface. Recent studies by Barrett et al., Wang et al., and King et al., have brought RH5-based vaccine development a step forward based on a rational antigen design strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama 790-8577, Japan.
- Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama 790-8577, Japan. Electronic address: tsuboi.takafumi.mb@ehime-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Takashima, E., & Tsuboi, T. (2024). RH5: rationally-designed malaria vaccine antigen improving efficacy. Trends in Parasitology. https://doi.org/10.1016/j.pt.2024.09.001
Vancouver
Takashima E, Tsuboi T. RH5: rationally-designed malaria vaccine antigen improving efficacy. Trends in Parasitology. 2024. doi:10.1016/j.pt.2024.09.001
BibTeX
@article{Takashima2024,
author = {Takashima, Eizo and Tsuboi, Takafumi},
title = {RH5: rationally-designed malaria vaccine antigen improving efficacy},
journal = {Trends in Parasitology},
year = {2024},
doi = {10.1016/j.pt.2024.09.001}
}
EUVIMED